This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Are Investors Undervaluing Bausch Health (BHC) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Bausch Health (BHC) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of 32.18% and 2.35%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Community Health's (CYH) Q3 Loss Widens, Admissions Drop
by Zacks Equity Research
Community Health (CYH) suffers from loss from drop in admissions.
Bausch Health (BHC) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Bausch (BHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for HCA Healthcare (HCA) in Q3 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) Q3 results are likely to be aided by strong revenues, driven by higher admissions.
Anthem (ANTM) Q3 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Anthem (ANTM) is likely to continue with its winning streak in the third quarter, backed by its Government Business as well as Commercial & Specialty Business segments.
Why Bausch (BHC) Could Beat Earnings Estimates Again
by Zacks Equity Research
Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bausch's Bryhali Gets Tentative FDA Nod for Plaque Psoriasis
by Zacks Equity Research
Bausch receives tentative FDA approval for the NDA for Bryhali (halobetasol propionate) Lotion, 0.01%, for the topical treatment of plaque psoriasis in adult patients.
Zacks.com featured highlights include: Bausch Health, Endava, DaVita, Perspecta and Athene Holding
by Zacks Equity Research
Zacks.com featured highlights include: Bausch Health, Endava, DaVita, Perspecta and Athene Holding
5 Dirt-Cheap PEG Stocks That Value Investors Love
by Zacks Equity Research
For investors looking to escape value traps, it is vital to determine where the stock is headed in the next 12 to 24 months.
Generic-Drugs Stock Outlook: No Respite from Pricing Issues
by Zacks Equity Research
Generic drugmakers, in general, are having a rather poor year, primarily due to ongoing pricing pressure and rising competition.
Progenics Pharma's Stock Down on Dismal Phase III Study Data
by Zacks Equity Research
Progenics Pharmaceuticals' (PGNX) shares down on disappointing results from phase III study evaluating imaging agent, 1404, for prostate cancer detection.
Should Value Investors Pick Bausch Health (BHC) Stock?
by Zacks Equity Research
Is Bausch Health (BHC) a great pick from the value investor's perspective right now? Read on to know more.
Company News For Sep 13, 2018
by Zacks Equity Research
Companies in the news are: GILD, VZ, BHC and WBC
Bausch (BHC) Looks Good: Stock Adds 13.9% in Session
by Zacks Equity Research
Bausch (BHC) shares rose nearly 14% in the last trading session, amid huge volumes.
Foamix's Acne Candidate Succeeds in Study, Shares Rally
by Zacks Equity Research
Foamix's (FOMX) acne candidate, FMX101, meets co-primary endpoints in the third phase III study, FX2017-22.
Bristol-Myers (BMY) Reports Phase II Data on Psoriasis Drug
by Zacks Equity Research
Bristol-Myers Squibb (BMY) announces encouraging data from a phase II study on plaque psoriasis candidate.
Why Is Bausch (BHC) Down 10% Since Last Earnings Report?
by Zacks Equity Research
Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bausch (BHC) Resubmits NDA for Duobrii for Plaque Psoriasis
by Zacks Equity Research
Bausch Health Companies Inc. (BHC) resubmits its NDA for plaque psoriasis drug, Duobrii to the FDA and the agency has set a PDUFA action date of Feb 15, 2019.
Bausch (BHC) Gets FDA Approval for Altreno for Acne Vulgaris
by Zacks.com
Bausch (BHC) advances its dermatology portfolio with the FDA approval of Altreno for acne vulgaris.
Aerie (AERI) Earnings Miss in Q2, Rhopressa Performs Well
by Zacks Equity Research
Aerie's (AERI) Q2 loss is wider than expected on account of higher expenses. Nevertheless, Rhopressa's sales beat estimates as demand picks up.
Bausch Health (BHC) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of 14.81% and 3.66%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Can Tenet Healthcare (THC) Keep Earnings Beat Alive in Q2?
by Zacks Equity Research
Tenet Healthcare (THC) is likely to repeat its success story in Q2 on the back of a strong performance at the Conifer segment as well as its key initiatives.